UK markets closed

BIOQUAL, Inc. (BIOQ)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
80.000.00 (0.00%)
At close: 03:14PM EDT

BIOQUAL, Inc.

9600 Medical Center Drive
Suite 101
Rockville, MD 20850-3336
United States
240-404-7654
https://www.bioqual.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Mark G. Lewis Ph.D.Chairman of the Board, CEO & PresidentN/AN/A1955
Mr. Charles C. Kirk Jr., CPAChief Financial OfficerN/AN/AN/A
Mitch FranklinChief Operating OfficerN/AN/AN/A
Ms. Hanne Andersen-Elyard Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

Corporate governance

BIOQUAL, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.